DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Paremyd (Hydroxyamphetamine Hydrobromide / Tropicamide Ophthalmic) - Summary

 
 



PAREMYD SUMMARY

PAREMYD sterile ophthalmic solution is a topical mydriatic combination product for ophthalmic use.

PAREMYD Solution is indicated for mydriasis in routine diagnostic procedures and in conditions where short-term pupil dilation is desired. PAREMYD provides clinically significant mydriasis with partial cycloplegia.


See all Paremyd indications & dosage >>

NEWS HIGHLIGHTS

Published Studies Related to Paremyd (Hydroxyamphetamine / Tropicamide Ophthalmic)

The clinical efficacy of paremyd with and without dapiprazole in subjects with light and dark brown irides. [1999.02]
BACKGROUND: Paremyd, a mydriatic formulation of 0.25% tropicamide and 1.0% hydroxyamphetamine hydrobromide provides adequate dilation for binocular indirect ophthalmoscopy in young Caucasians. We studied the clinical effectiveness of Paremyd in dilating heavily pigmented eyes by comparing its mydriatic efficacy in Blacks, Asians and Caucasians with light and dark brown irides. We also evaluated the efficacy of one drop of dapiprazole (Rev-Eyes) in reversing Paremyd-induced mydriasis in our subject sample... CONCLUSIONS: Our data indicate that a single drop of Paremyd provides adequate mydriasis, without significant side effects, for routine fundus examination of all subjects, independent of iris color/pigmentation. Furthermore, a single drop of dapiprazole was effective in speeding the return of pupillary dilation in most subjects, but had no significant effect on accommodation, near visual acuity or glare discomfort. Side effects such as stinging upon instillation, conjunctival hyperemia, and a few instances of ptosis, with possible additional cost to patients, appear to lessen its overall clinical benefit.

Comparison of efficacy and tolerance between 1% hydroxyamphetamine plus 0.25% tropicamide (Paremyd) and 0.5% tropicamide combined with 2.5% phenylephrine. [1996.11]
BACKGROUND: Paremyd, consisting of a combination of 1.0 percent hydroxyamphetamine and 0.25 percent tropicamide, is a commercially available eyedrop used clinically for diagnostic mydriasis. This study sought to determine if one drop of Paremyd is equally effective and tolerable as the traditional combination of one drop each of 2.5 percent phenylephrine and 0.5 percent tropicamide... CONCLUSIONS: Paremyd appears to be as effective a mydriatic as TP, but with greater comfort on instillation. Paremyd has less effect on accommodation.

Ideal concentration of tropicamide with hydroxyamphetamine 1% for routine pupillary dilation. [1989.09]
In this double-masked clinical study, we evaluated four concentrations of tropicamide (0.05%, 0.1%, 0.25%, and 0.5%) combined with hydroxyamphetamine 1% to find the combination that gives maximal pupillary dilation and inhibition of responsiveness to light and minimal paralysis of accommodation... Tropicamide 0.25% combined with hydroxyamphetamine 1% was considered ideal for dilation and inhibition of the light response without inhibiting accommodation for near vision.

Pupillary dilation and funduscopy with 1.0% hydroxyamphetamine plus 0.25% tropicamide (Paremyd) versus tropicamide (0.5 or 1.0%) as a function of iris and skin pigmentation, and age. [1996.11]
BACKGROUND: This study was designed to evaluate the effect of Paremyd, a combination of 1.0 percent hydroxyamphetamine hydrobromide and 0.25 percent tropicamide, on pupil size during binocular indirect ophthalmoscopy (BIO) upon 164 subjects of various skin pigmentation, iris color, and age... CONCLUSIONS: Paremyd, because of its superior effect upon dilation without side effects, can be the preferred agent used for routine single-drop dilation in all patients, independent of age, iris color, or skin color.

more studies >>


Page last updated: 2008-08-10

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2012